MedTrace Logo

A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

NCT03622216 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-06-20

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough

Conditions

  • Chronic Cough

Interventions

DRUG

Bradanicline

Three different doses over the course of the study

DRUG

Placebo

Matching placebo for Bradanicline

Sponsors & Collaborators

  • Attenua, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Attenua, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-05
Primary Completion
2019-05-07
Completion
2019-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03622216 on ClinicalTrials.gov